Latest Monoclonal antibody therapy Stories
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
SUZHOU, China, Dec. 8, 2014 /PRNewswire/ -- Adagene Inc.
Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies INDIANAPOLIS and VANCOUVER, Oct. 22, 2014 /CNW/ - Zymeworks Inc.
SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D.
AbGenomics raised new fund for advancing its mid-stage clinical trials LOS ALTOS, Calif., Oct.
-Enhances Capabilities for the Precision Medicine in Immuno-oncology and Autoimmune Disease Areas- LOS ANGELES and LEIPZIG, Germany, Sept. 17, 2014 /PRNewswire/ -- ImaginAb, Inc.
SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease SAN DIEGO, Sept.
SEATTLE and VANCOUVER, British Columbia, Sept.
Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept.
- To swell, as grain or wood with water.